Back to Search Start Over

Interferome signature dynamics during the anti-dengue immune response: a systems biology characterization.

Authors :
Usuda JN
Plaça DR
Fonseca DLM
Marques AHC
Filgueiras IS
Chaves VGB
Adri AS
Torrentes-Carvalho A
Hirata MH
Freire PP
Catar R
Cabral-Miranda G
Schimke LF
Moll G
Cabral-Marques O
Source :
Frontiers in immunology [Front Immunol] 2023 Aug 10; Vol. 14, pp. 1243516. Date of Electronic Publication: 2023 Aug 10 (Print Publication: 2023).
Publication Year :
2023

Abstract

Dengue virus (DENV) infection manifests as a febrile illness with three distinct phases: early acute, late acute, and convalescent. Dengue can result in clinical manifestations with different degrees of severity, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. Interferons (IFNs) are antiviral cytokines central to the anti-DENV immune response. Notably, the distinct global signature of type I, II, and III interferon-regulated genes (the interferome) remains uncharacterized in dengue patients to date. Therefore, we performed an in-depth cross-study for the integrative analysis of transcriptome data related to DENV infection. Our systems biology analysis shows that the anti-dengue immune response is characterized by the modulation of numerous interferon-regulated genes (IRGs) enriching, for instance, cytokine-mediated signaling (e.g., type I and II IFNs) and chemotaxis, which is then followed by a transcriptional wave of genes associated with cell cycle, also regulated by the IFN cascade. The adjunct analysis of disease stratification potential, followed by a transcriptional meta-analysis of the interferome, indicated genes such as IFI27 , ISG15 , and CYBRD1 as potential suitable biomarkers of disease severity. Thus, this study characterizes the landscape of the interferome signature in DENV infection, indicating that interferome dynamics are a crucial and central part of the anti-dengue immune response.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Usuda, Plaça, Fonseca, Marques, Filgueiras, Chaves, Adri, Torrentes-Carvalho, Hirata, Freire, Catar, Cabral-Miranda, Schimke, Moll and Cabral-Marques.)

Details

Language :
English
ISSN :
1664-3224
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
37638052
Full Text :
https://doi.org/10.3389/fimmu.2023.1243516